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Background: Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treat-
ment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiﬂammatory phar-
maceuticals. Omega-3 (n3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in
dogs.
Objective: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of sup-
plementation on the arachadonic acid (ARA)/ (EPAþDHA) algorithm and 3) to correlate alterations in the
ARA/(EPAþDHA) with changes in the clinical signs of canine OA.
Methods: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind,
placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an
average dose of 69 mg EPAþDHA/kg/day). Orthopedic examinations and blood analyses were performed
at baseline, day 42, and day 84. A single investigator conﬁrmed a diagnosis of OA of the coxofemoral
joints and/or stiﬂe joints in all dogs.
Results: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness,
and joint severity at day 84 and all blood metrics at day 42 and day 84 signiﬁcantly (po0.05) improved
compared with placebo. No major side effects were observed.
Conclusion and clinical relevance: This study demonstrated that the daily supplementation of a dogs diet
with EPA and DHA shifts the blood fatty acid concentrations correlating to relief of clinical signs asso-
ciated with OA in dogs.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Ltd. This is an open access article u
cosahexaenoic acid; ALA, α-
e membrane, n3 omega-3
tis; iFATS, inﬂammatory fatty
Finley, Dr. Carrie Woodcock,
Hauptman for his statistical
CK conducted research; SM,
M wrote the paper. SM had
read and approved the ﬁnal
ian Recommended Solutions,
9462, United States.
er).1. Introduction
OA affects up to 20% of dogs 41 year of age [1]. The disease
afﬂicts dogs of all breeds and ages. Common approaches to the
disease include attempts at prevention, slowing progression, and
managing the clinical signs associated with OA. These are ac-
complished with appropriate nutrition, body- weight control, ex-
ercise, physical therapy, and anti-inﬂammatory and analgesic
medications [2,3]. Nonsteroidal anti-inﬂammatory drugs (NSAID)
are effective modes of treatment, but have potential negative
systemic side effects such as gastrointestinal ulceration, liver and
kidney damage, and accelerated cartilage degeneration [3,4]. There
is a pressing need for safe alternatives to manage OA. Previous
studies in dogs have supported the efﬁcacy of the marine n3
fatty acids in OA [2,3,5,6–8.]nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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C20:5n3), DHA (docosahexaenoic acid, C22:6n3), and ALA
(alpha-linolenic acid, C18:3n3). Both EPA and DHA are found in
high concentrations in ﬁsh oils. Both EPA and DHA have potent
anti-inﬂammatory properties, and DHA is a major component of
the central nervous system. ALA is found in some seed oils (e.g.,
ﬂaxseed oil) and requires the enzymes delta-6 and delta-5 desa-
turases to convert it into EPA and DHA in the body [5,7–11]. Dogs
have a limited ability to accomplish this conversion [5,9,10,12],
therefore providing preformed EPA and DHA is the most efﬁcient
way to increase tissue concentrations of these fatty acids. The
other family of essential fatty acids are the n6 fatty acids in-
cluding LA (linoleic acid, C18:2n6), GLA (gamma-linolenic acid,
C18:3n6), and ARA (arachidonic acid, C20:4n6). The former
two, especially LA, are found primarily in vegetable oils and food
products made with them. ARA is metabolized through multiple
pathways (cyclooxygenase, lipoxygenase, cytochrome P450
monooxygenases, etc.), and some of its metabolites are in-
ﬂammatory mediators [13]. EPA and/or DHA, can be utilized to
decrease the amount of ARA available as a substrate for in-
ﬂammatory eicosanoid production. The body needs episodic in-
ﬂammation to heal wounds and ﬁght infection, but chronic in-
ﬂammation can lead to chronic disease.
Consuming ﬁsh oils results in the partial replacement of ARA in
cell membranes by EPA and DHA. This leads to decreased avail-
ability of ARA for conversion into leukotrienes and prostaglandins
[14,15]. EPA and DHA give rise to lesser inﬂammatory molecules
(e.g., prostaglandin E3, leukotriene B5) with a resultant competi-
tive inhibition of ARA metabolism [11]. The net effect is a reduc-
tion in the anti-inﬂammatory environment systemically and
within the joint.
The primary goals of this study were (1) to determine the ef-
fects of daily supplementation of a natural triglyceride form of EPA
and DHA (in a ratio of 3:2; Canine Omega Beneﬁts, Veterinarian
Recommended Solutions, Plymouth Meeting, PA) on the clinical
signs of OA in dogs, (2) to evaluate the effects of supplementation
on the blood ARA/EPAþDHA ratio (Inﬂammatory Fatty Acid target
Score, iFATS™), and (3) to correlate changes in the iFATS with
changes in OA clinical signs.2. Materials and methods
2.1. Design
This was a prospective, randomized, double blind, placebo
controlled study. Any dog greater than 2 years of age with natu-
rally occurring OA of the stiﬂe or coxofemoral joint as previously
diagnosed by a veterinarian physical examination and radiographs
was eligible to participate. Exclusion criteria included any dog
with a disease in which surgery was recommended (cruciate li-
gament instability, grade two medial or lateral patella luxation, hip
luxation or signiﬁcant subluxation), concurrent active neurologic
conditions, any comorbidity causing weakness or discomfort in the
limbs not directly related to osteoarthritis, or current administra-
tion of an n3 supplement or diet supplemented with n3. Pa-
tients previously taking NSAIDs were enrolled if the pet owner
refrained from administering the NSAID for two weeks or more
before enrollment. If dogs required rescue analgesia during the
trial, they were removed from the study and referred to their
primary veterinarian. The data from these dogs was not included
in the ﬁnal analysis. Dogs were recruited from and evaluated at
four primary care practices1. All pet owners were educated on the1 Macungie Animal Hospital, Macungie, PA; VCAWellington, Newtown Square,study, the product and placebo, and each owner signed a consent
form prior to enrolment. All examinations, blood work, and pro-
duct were administered at no cost to the owner. All animals in this
study were the property of a responsible adult pet owner that
consciously consented to the participation of their pet in the study.
No Animal Use Committee was consulted with for the study;
however, a standardized pet owner consent and acknowledgment
form was described to and read and signed by every pet owner
and each medical director of the participating clinic read and ac-
knowledged the study protocol prior to initiating the trial. All
physical examinations and blood collections were performed in a
routine manner and in the presence of the pet owner. The ARRIVE
guidelines were complied with during the entire clinical trial.
2.2. Interventions
The active treatment group received the n3 product and the
placebo group received a medical grade mineral oil. The n3
product contained EPA and DHA, derived from a mixture of an-
chovy, sardine, and mackerel, in a ratio of 3:2 in a natural trigly-
ceride form. Both oils were distributed in 500 mL, tinted glass
bottles with a pump that delivers 3 mL per pump. The label on the
outside of the bottle contained a randomized study number, as-
signed by the study statistician, who also maintained all blinding,
held the key for randomization, and performed all data analysis.
No block randomization was performed. The number of pumps to
deliver to the patient's food dish per day was based on body
weight and written on the bottle label. The pet owner was in-
structed to administer the daily dose once per day either with the
morning or evening feeding but that the frequency and time of
dosing was consistent throughout the study period. Each mL of the
n3 product contained 240 mg of combined EPA and DHA. Dosing
schedules for the study were as recommended by the manu-
facturer: 1 pump (720 mg EPA and DHA) for dogs weighing 4.5–
13.6 kg, 2 pumps (1440 mg of EPA and DHA) for 13.7–27.2 kg;
3 pumps (2160 mg of EPA and DHA) for 27.3–40.8 kg, and 4 pumps
(2880 mg of EPA and DHA) for dogs weighing greater than 40.8 kg.
2.3. Assessments
Compliance was assessed by having an independent study
technician weigh each bottle at day 42 and day 84 and compare
that information to the amount of doses recommended to be ad-
ministered per day.
A single investigator (SJM) blinded to treatment assignment
conducted all clinical examinations. Radiography and physical
examination were used to conﬁrm a diagnosis of OA. Evaluations
by the investigator included a physical examination, a lameness/
discomfort visual analogue scale (VAS), a lameness/discomfort
severity grade, and an individual and total joint score; and at day
42 and 84 an investigator improvement VAS.
The Lameness/Discomfort VAS is a 10 cm scale on the vertical
axis. At the bottom is a description of a normal dog and at the top
of the scale is a description of a dog debilitated by OA. A horizontal
line is drawn on the scale that best describes the pet on that day. A
ruler is used to measure from baseline to the horizontal line and is
recorded in centimeters.
The Lameness Grade is derived from a series of numbers (0–10)
spaced evenly across the top of the evaluation form. The investigator
circles the number that best describes the pet on that day. Zero re-
presents a normal dog and 10 represents a dog debilitated by OA.(footnote continued)
PA; West Chester Veterinary Rehabilitation Specialty Center, West Chester, PA;
Leigh Valley Veterinary Dermatology Center, Allentown, PA.
S.J. Mehler et al. / Prostaglandins, Leukotrienes and Essential Fatty Acids 109 (2016) 1–7 3The Individual Joint Score is derived from an evaluation of the
left and right stiﬂe and left and right coxofemoral joints. All four
joints were scored in each dog. For each joint, three variables are
measured at each time period: effusion, pain on palpation or range
of motion, and crepitus. Each variable for each joint was scored
0–3 (no pathology to severe). Points for each variable, each joint,
and total points per patient were computed.
The Improvement Scale is a 10 cm scale on the vertical axis,
with “no improvement” at the bottom and “complete return to
normal” at the top. The investigator placed a horizontal line to best
describe the patient on that day. The distance (cm) was recorded
from zero (the base of the vertical line) to the drawn horizontal
bar.2.4. Laboratory methods
A 0.2 mL of whole blood was collected using a peripheral vein
from each patient at baseline, day 42, and day 84. An aliquot of
25 uL was placed on an anti-oxidant treated card and allowed to
air dry. Cards were then sent to OmegaQuant Analytics, LLC (Sioux
Falls, SD) where the blood fatty acid composition was measured
using capillary column gas chromatography as previously de-
scribed [15]. From the fatty acid data, the iFATS was calculated.b2.5. Pet foods
All 22 diets were purchased from local pet stores or from an
online distributer. If the manufacturer was willing to release label
information of fatty acid proﬁle of the speciﬁc diet, it was re-
corded. For any company that would not disclose such informa-
tion, the sealed bag of pet food was submitted for fatty acid ana-
lysis at an independent laboratory (Table 1).Table 1
The partial fatty acid proﬁle and total omega-6 to omega-3 ratio (N-6:N-3) re-
presenting the 22 diets that dogs in the study were reported to be consuming
during the trial period. C18:2n6 is ARA, C18:3n3 is ALA, C20:5n3 is EPA, and
C22:6n3 is DHA. The individual data presented in this table represent the per-
centage of a particular fatty acid present within the cell membrane of the ery-
throcyte in relationship to total fatty acid content of the membrane. The N-6:n3
ratio is unitless.
Diet C18:2n6 C18:3n3 C20:5n3 C22:6n3 Total N-6:N-3
a 31.83 1.36 2.00 1.98 6.17
b 18.88 1.02 1.88 0.63 5.53
c 8.45 0.44 0.28 0.21 9.44
d 26.71 3.05 0.01 0.03 8.73
e 12.82 4.27 0.01 0.02 3.04
f 31.39 2.19 0.01 0.03 14.22
g 7.83 0.38 0.00 0.01 19.91
h 25.55 2.90 2.08 1.53 4.01
i 25.60 1.53 0.04 0.07 16.06
j 19.75 14.05 4.42 2.86 0.95
k 11.11 0.78 0.10 0.22 10.33
l 8.23 2.80 0.20 0.14 2.69
m 18.00 3.44 0.28 0.21 4.67
n 24.20 3.05 0.04 0.05 7.81
o 30.20 1.88 2.00 1.98 5.30
p 18.20 4.70 1.88 0.63 2.62
q 13.00 4.12 0.12 0.10 3.07
r 31.10 2.19 0.05 0.07 13.63
s 22.20 3.88 0.08 0.10 5.50
t 19.20 5.30 1.00 1.20 2.64
u 14.84 3.37 0.62 0.30 3.56
Average 19.96 3.18 0.81 0.59 7.142.6. Statistical methods
The data were not normally distributed, Wilcoxon rank sum
test were performed on all data, testing for differences between
groups at each time, and differences between times for each group
(Wilcoxon signed rank test). There were two treatment time
points, days 42 and 84, and the changes from time 0 (baseline)
were compared between groups. The Type I error rate was pro-
tected by means of Bonferroni P, P/m where P¼0.05 and m¼the
number of comparisons. Data were presented as median (Inter-
quartile Range) and Po0.05 was considered signiﬁcant. Pearson's
product moment correlation coefﬁcient, r, was used to measure
the strength and direction of the linear relationship between two
normally distributed variables, in this case, the relationship be-
tween the iFATS and speciﬁc orthopedic outcome variables at day
0 and day 84. The value of r is assumed to be between þ1 and 1.
All statistical analysis was performed using a SAS 9.3 (Cary, NC).3. Results
One hundred dogs were evaluated for inclusion in the trial.
Twenty-two dogs, ﬁfteen in the placebo group and seven in the
treatment group, were not included in the ﬁnal analysis of the
study because they had a surgical orthopedic condition diagnosed
at the base line examination or between the baseline and the 42-
day evaluation. Another four dogs were removed from the ﬁnal
analysis; two dogs in the placebo group required rescue analgesia
(in the form of an NSAID) between days 42 and 84 and were re-
moved from the trial. One dog in the active group developed acute
left thoracic limb lameness and was diagnosed with metastatic
squamous cell carcinoma of the nail bed and was euthanatized
between the 42-day and the 84-day evaluation. One dog in the
treatment group did not present for the 84-day evaluation and
was removed from the study. There were 41 dogs in the treatment
group and 33 dogs in the placebo group that completed the study.
The treatment group included 10 Labrador retrievers, 2 golden
retrievers, 3 pit-bull terriers, 2 bulldogs, 9 mix breed dogs, and one
each of a cockapoo, smooth coated collie, miniature poodle,
standard poodle, wire pointing griffon, giant schnauzer, pug,
German shepherd, German shorthair pointer, basset hound, bichin
frise, old English mastiff, Shetland sheepdog, Chihuahua, and an
Australian shepherd. In the placebo group there were 8 Labrador
retrievers, 3 pit-bull terriers, 9 mix breed dogs, 2 German shep-
herds, and one each of a Welsh corgi, King Charlers Cavalier,
miniature schnauzer, Great Dane, Saint Bernard, Bernese mountain
dog, Pomeranian, Shiba Inu, husky, basset hound, and a Bouvier
des Flanders. Mean ages of the two groups were 7.3 (2–12.5) and
8.5 (2–14) years, respectively. The treatment group included 25
spayed females and 14 castrated males; for the placebo group, 14
spayed females, 18 castrated males and 1 intact male. There was no
relationship between breed, sex, age, or weight and any of the
outcome metrics. The average dose of combined EPA and DHA
received by dogs in the study was 68.9 mg/kg/day (33–103.4 mg/
kg/day).
3.1. Bottle weights and compliance
All bottles were weighed at baseline, day 42, and day 84 for
each dog. Expected weights of bottles were calculated for each
weight class and compared to the measured weights. There were
no signiﬁcant differences in the weights of the bottles for each
weight class between the treatment and placebo group.
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Investigator assessment results are represented in Figs 1–4.
Compared with the placebo group, there was a signiﬁcant im-
provement in the treatment group at day 42 and day 84 for the
Total Joint Score (po0.001) and the Improvement VASFig. 1. Box and whisker plot Investigator Visual Analogue Scale for Discomfort/
Lameness. This is a 10 cm vertical scale. The plots represent the median, 25–75
quartiles, and minimum and maximum data points. A signiﬁcant decrease in dis-
comfort and lameness occurs in the treatment group compared to the placebo
group at the 84 day time point. *po0.001.
Fig. 2. Box and whisker plot Investigator 10 Point Severity Grade for Lameness. The
plots represent the median, 25–75 quartiles, and minimum and maximum data
points. A signiﬁcant decrease in the lameness grade occurs in the treatment group
compared to the placebo group at the 84 day time point. *po0.001.
Fig. 3. Box and whisker plot Investigator Visual Analogue Scale for overall Im-
provement. The plots represent the median, 25–75 quartiles, and minimum and
maximum data points. A signiﬁcant improvement in overall lameness, function,
and comfort was observed in the treatment group compared to the placebo group
at day 42 and day 84. *po0.001.
Fig. 4. Box and whisker plot The Total Joint Severity Score. The plots represent the
median, 25–75 quartiles, and minimum and maximum data points. The total score
was calculated by adding the scores from the assessment of three variables, pain,
crepitus, and effusion rated from 0 (normal) to 3 (most severe) for each joint. There
is a statistically signiﬁcant improvement in the total point score for all joints at day
42 and day 84 in the treatment group compared to the placebo group. * po0.0001.(po0.0001). On day 42, there was no signiﬁcant difference be-
tween the placebo and treatment groups for the Lameness/Dis-
comfort VAS and the Lameness Severity Score; however, both
outcome variables demonstrated a signiﬁcant difference at the day
84-time point (po0.001).
3.3. Blood fatty acid metrics
The individual EPA, DHA, and ARA values are listed in Table 2,
as is the individual iFATS. The iFATS was signiﬁcantly decreased
(po0.001) in the treatment group (Fig. 5) at days 42 and 84. The
effects of n3 treatment on the iFATS were similar at days 42 and
84.
3.4. Correlation between the change in the iFATS and Clinical
Outcomes
At baseline, for the 74 dogs that completed the trial, a corre-
lation coefﬁcient of r¼0.74 was calculated between the iFATS and
the Lameness Severity Score and a correlation coefﬁcient of
r¼0.73 was calculated between the iFATS and the Lameness/Dis-
comfort VAS. The correlation coefﬁcient calculated between the
iFATS and the Total Joint Score was r¼0.03. The 84-day data was
also evaluated for an existing correlation to each outcome variable
and the iFATS. The correlation coefﬁcient between the Lameness
Severity Score in the 74 dogs and the iFATS at day 84 was r¼0.75,
and for the Lameness/Discomfort VAS and the iFATS was r¼0.67.
The correlation coefﬁcient identiﬁed between the Total Joint Score
and the iFATS at day 84, was r¼0.37. These results indicate a
strong positive correlation between the iFATS at baseline and at
day 84 with the Lameness Severity Score and the Lameness/Dis-
comfort VAS but no correlation exists between the iFATS and the
Total Joint Score.
3.5. Adverse events
Four adverse events were reported during the trial, two in each
group. One dog from each group developed diarrhea during the
ﬁrst week of the study. Both were prescribed metronidazole for
1 week and were able to continue in the study. Two other dogs
developed food aversion at day 2–3 of the study. In both cases,
normal dry food was replaced with canned food and this resolved
the aversion.
Fig. 5. Box and whisker plot of the ARA/(EPAþDHA) ratio. The plots represent the
median, 25–75 quartiles, and minimum and maximum data points. There is a
statistically signiﬁcant decrease in the ARA/(EPAþDHA) ratio in the treatment
group compared to the placebo group at day 42 and day 84. * po0.0001.
Table 2
The median, interquartile range (IQR) low and high for EPA, DHA, ARA, and iFATS for both the placebo and active treatment groups at day 0 and day 84.
EPA DHA ARA ARA/ EPAþDHA
Day 0 Day 84 Day 0 Day 84 Day 0 Day 84 Day 0 Day 84
Placebo Median 0.50% 0.40% 0.98% 0.95% 21.00% 20.50% 14.77 14.88
IQR Low 0.20% 0.20% 0.69% 0.43% 17.80% 17.25% 7.93 7.29
IQR High 1.00% 0.80% 1.92% 1.64% 23.15% 22.90% 24.29 24.46
Active Median 0.20% 2.70% 0.64% 2.13% 22.40% 18.50% 28.31 3.48
IQR Low 0.10% 1.85% 0.33% 1.81% 19.40% 15.45% 15.12 2.86
IQR High 1.10% 3.40% 0.99% 2.58% 24.40% 20.65% 45.03 4.83
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The main ﬁndings of this study were that treatment with a
triglyceride form of EPA and DHA (average dose of 68.9 mg/kg/
day) for 84 days improved all investigator-assessed clinical mar-
kers of OA. The methods of clinical evaluation were chosen based
on recent publications validating the use of these techniques to
assess improvements in lameness and pain in dogs with OA [2,6–
8,16,17–25]. The crepitus, pain, and effusion scores and the overall
improvement scales had signiﬁcantly improved in dogs in the
treatment group compared to the placebo group by day 42 but the
discomfort scales and lameness grades did not signiﬁcantly im-
prove until day 84. Blood concentrations of ARA changed rapidly in
dogs receiving EPA and DHA supplementation and may be asso-
ciated with a more rapid decrease in the clinical signs associated
with inﬂammation (effusion and pain) of the joint and an early
and obvious overall improvement. While the clinical signs asso-
ciated with compensatory mechanisms, chronic nerve stimulation,
and muscle atrophy, that contribute to clinical lameness and dis-
comfort, will likely take longer to improve and may be the reason
why these particular parameters improved at 84 days and not at
42 days. The clinical signiﬁcance of the statistical ﬁndings was
readily apparent during the trial. Patients receiving daily supple-
mentation of ﬁsh oil had consistent clinical improvements in their
pain, dysfunction, and overall well-being by the conclusion of the
trial.
There are numerous reports documenting the biochemical
beneﬁts of diets enriched or supplemented with EPA and DHA in
dogs with OA [2,5,7,8,25,26–30]. The mechanisms in which EPA
and DHA interact with the inﬂammatory system have been re-
ported and include the suppression of proinﬂammatory mediators
IL-1, IL-2, and tumor necrosis factor in cartilage [31]. modiﬁcation
of COX-2 and 5-LOX metabolism of ARA [32], a decrease in ex-
pression of pro matrix metalloproteinases (MMP's) and urokinaseplasminogen activator, and increases in tissue inhibitors of MMP-2
[15] Clinical improvements have also been documented, including
improvements in lameness, weight-bearing scores, and force-plate
analysis [8]. In a multicenter study, dogs fed a diet enriched with
EPA and DHA had a signiﬁcantly higher serum concentration of
total n3 fatty acids and a signiﬁcantly lower serum concentra-
tion of ARA at 6, 12, and 24 weeks and, according to owners, dogs
fed the test food had a signiﬁcantly improved ability to rise from a
resting position and play at 6 weeks and improved ability to walk
at 12 and 24 weeks [2]. In another multicenter study evaluating
the effect of dietary supplementation with n3 fatty acids on
carprofen dosage in dogs with OA, the investigators found that the
intervention allowed for a reduction in carprofen dosage over time
[7]. Other studies have evaluated the effect of an EPA and DHA
enriched diet on the clinical signs of OA and plasma concentra-
tions of fatty acids [2,8] but the application of EPA and DHA to a
variety of commercial diets in dogs with OA has not been eval-
uated in combination with using whole blood ratios of ARA/
(EPAþDHA).
The hypothesis of this study was that dogs with clinical signs of
OA would beneﬁt clinically and would experience an increase in
the blood ARA/(EPAþDHA) ratio after supplementation of a tri-
glyceride form of EPA and DHA. In the absence of these two fatty
acids, cells incorporate ARA (whether consumed preformed in the
diet or produced from dietary LA) into cell membranes resulting in
the ultimate production of a suite of inﬂammatory mediators at
sites of injury or disease. Increased consumption of EPA and DHA
raise their own tissue concentrations and, at the same time, lowers
ARA concentrations by inhibiting its synthesis from LA and by
competition for esteriﬁcation into a ﬁnite number of plasma
phospholipid molecules. Thus, higher EPAþDHA intake lowers
ARA and markedly lowers the iFATS. The manufacturers re-
commended dose is lower than the dose historically re-
commended to treat OA in dogs. The discrepancy in dosage re-
commendations is related to form. It is known in mammals that
absorption, and therefore bioavailability, of a natural or reester-
iﬁed triglyceride form of ﬁsh oil is signiﬁcantly more efﬁcient than
the ethyl ester form of ﬁsh oil [5,33]. The historically studied and
reported form of ﬁsh oil used in dogs to treat OA has been in the
ethyl ester form and therefore a higher dose of combined EPA and
DHA is required to achieve plasma or erythrocyte membrane levels
similar to a lesser dose of a triglyceride form of EPA and DHA.
It was also hypothesized that a correlation would exist between
the iFATS and the orthopedic clinical outcome variables. At base-
line and at day 84 of the trial, the iFATS was positively correlated
with the Lameness Severity Score and the Lameness/Discomfort
VAS but not with the Total Joint Score at either time point. If there
is less ARA in the tissues of the body, an indirect measure of the
iFATS, then there should be less inﬂammation produced by the
ARA cascade yielding less clinical signs associated with OA. This is
likely a part of the mechanism correlating a lower iFATS with a less
severe lameness and discomfort. One justiﬁcation for the lack of a
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the deﬁnition of the Total Joint Score. A dog with a severely ar-
thritic left stiﬂe joint may have a severe lameness and discomfort
in that leg and a relatively high iFATS, and because only one joint is
affected in this case, the Total Joint Score will be high for that joint
but low for the other joints. This is in comparison to a dog with
minimal OA in 5 different joints. This second patient may have a
high Total Joint Score because of the number of effected joints
involved in the scoring is 5 compared to 1, but the patient is ex-
pected to have minimal lameness and a relatively low iFATS.
In clinical experience, OA can occur in dogs that are on a variety
of individual diets representing a wide range of n6:n3 ratios.
Because of the addition of ﬂaxseed oil (which contains 55% ALA) or
even soybean oil (7% ALA) to pet foods [34], the n6:n3 ratio in
the food can be rather easily manipulated, but ALA is not EPA or
DHA, and conversion of ALA to these long chain metabolites is
quite inefﬁcient in dogs. Hence, the claim that a product has a
given n6:n3 ratio is relatively meaningless unless the speciﬁc
fatty acids that comprise the ratio are listed. A ratio of 4:1, for
example, would be considered strongly anti-inﬂammatory if the
majority of the n3 was in the form of EPA and DHA, but it would
likely have minimal effect on the inﬂammatory processes if the
n3 was predominantly ALA. This is why blood levels of ARA in
comparison to EPA and DHA have come to be recognized as more
physiologically relevant than n6:n3 ratios [35]. There were 22
different commercial diets represented in the study. Although no
speciﬁc diet or diet type could be directly linked to a level of
baseline n3 deﬁciency in our study, many of the diets with ad-
ded n3 represented in our study used ALA. The results of our
study demonstrated that, even without knowledge of the back-
ground diet's n6:n3 ratio, the daily administration of EPA and
DHA to dogs in the treatment group signiﬁcantly lowered systemic
ARA concentrations and elevated EPA and DHA concentrations and
improved their clinical signs associated with OA.
The ARA/(EPAþDHA) ratio of whole blood correlates strongly
with that of erythrocyte membranes (r¼0.94, n¼50 unpublished
data), which are themselves a valid reﬂection of the poly-
unsaturated fatty acid composition of other cell membranes
throughout the body [36,33,37]. This method of assessment was
chosen because there is considerably more day-to-day variation in
plasma fatty acid levels than in whole blood or erythrocyte
membrane [38,39.]
Baseline concentrations of EPA and DHA in the dogs enrolled in
the study were low, and ARA concentrations were elevated com-
pared to the post treatment levels indicating a possible pattern in
the fatty acid ratio of the dogs’ diets. Patients in the treatment
group had a correction of this imbalance with daily supple-
mentation with EPA and DHA. The signiﬁcant decrease in ARA
(about 17%), and the signiﬁcant increase in EPA (13.3-fold) and
DHA (3.3-fold) correlated with signiﬁcant changes in the comfort
and function of patients in the treatment group.
The n3 triglyceride supplement evaluated in this study ap-
peared to be safe for daily ingestion. A total of 4 dogs developed
gastrointestinal side effects, two of which were in the treatment
group, which may have been attributable to the administration of
ﬁsh oil. In all 4 cases, the signs resolved within a few days.
One of the limitations in this study was a relatively small
number of patients and the intervention was applied over a rela-
tively short time period. Longer and larger studies are needed to
conﬁrm the prolonged improvement in clinical signs observed
here. Strengths of the study include the methods of assessing
discomfort, lameness, and joint health which were based on pre-
viously validated techniques [2,6–8,16,17–25]. Having outcomes
assessed by a single (blinded) investigator eliminated bias [2,8,18].
The use of a reﬁned visual analogue and scoring scale, a validated
composite score, and force plate analysis may be helpful in futurestudies to examine differences in investigators’ and owners’ as-
sessments. Finally, variability in diets before and during the trial
could be considered a limitation or weakness; however, it may
also be viewed as a strength since the diets represented here are
characteristic of the clinical environment. This variability pre-
sumably contributed to differences in baseline fatty acid levels, but
the majority of patients demonstrated patterns that were asso-
ciated with worse clinical features of OA that were signiﬁcantly
altered in the treatment group by day 84.5. Conclusion
Our ﬁndings suggest that the daily ingestion of EPA and DHA is
safe for dogs with OA and improves the clinical signs, and this
improvement is associated with a marked reduction in the ratio of
ARA to EPA and DHA in the blood. Additional studies are needed to
assess the longer-term effects of supplementation with this pro-
duct on OA. Additional endpoints in such studies could include
synovial ﬂuid analysis of the enzymes known to damage articular
cartilage, force plate analysis, and possibly a head-to-head com-
parison with NSAID agents and/or other forms of EPA and DHA.Disclosures
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